WC
RARE icon

Woodstock Corp’s Ultragenyx Pharmaceutical RARE Stock Holding History

Woodstock Corp’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-9,191
Closed -$307K – 166
2026
Q2 		$307K Buy
+9,191
New +$228K 0.03% 137
2025
Q4 		– Sell
-18,114
Closed -$545K – 158
2025
Q3 		$545K Buy
18,114
+4,827
+36% +$145K 0.05% 116
2025
Q2 		$483K Sell
13,287
-584
-4% -$21.1K 0.04% 118
2025
Q1 		$502K Hold
13,871
– – 0.05% 116
2024
Q4 		$584K Hold
13,871
– – 0.06% 113
2024
Q3 		$771K Hold
13,871
– – 0.07% 107
2024
Q2 		$570K Buy
13,871
+2,747
+25% +$117K 0.06% 113
2024
Q1 		$519K Buy
11,124
+3,064
+38% +$145K 0.05% 119
2023
Q4 		$385K Buy
+8,060
New +$312K 0.04% 129
2019
Q4 		– Sell
-11,212
Closed -$480K – 157
2019
Q3 		$480K Hold
11,212
– – 0.08% 120
2019
Q2 		$712K Hold
11,212
– – 0.12% 105
2019
Q1 		$778K Buy
+11,212
New +$641K 0.14% 102

Other funds holding RARE

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
MWP
Meriwether Wealth & Planning Minden, Louisiana $222M AUM 15.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Woodstock Corp's RARE Position: Q3 2026 in Review

Woodstock Corp sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2026, closing a stake of 9,191 shares — an estimated $307K sold.

Woodstock Corp first reported a position in RARE in Q1 2019 and held it in 12 quarters. The position peaked at $778K in Q1 2019. 8 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Woodstock Corp reported no remaining Ultragenyx Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Woodstock Corp sold 9,191 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $307K.
  • Woodstock Corp first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 12 quarters.
  • Woodstock Corp's Ultragenyx Pharmaceutical position peaked at $778K in Q1 2019.
  • 8 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Woodstock Corp's 13F filing for Q3 2026, filed 13 Oct 2026.